secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001193125-24-165651
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics COO steps down; Huw Nash remains as Chief Business Officer
-----------------------------------------------------------------------------

- Huw Nash, Ph.D., stepped down as COO effective June 18, 2024, by mutual agreement with the company.
- Nash continues in his role as Chief Business Officer, retaining business development responsibilities.
- No successor Chief Operating Officer was named; the COO position appears eliminated or duties reassigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524165651/0001193125-24-165651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524165651/d856457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-165651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer